Shuangyue Wu

Ms. Shuangyue Wu

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2026 in International Dental Journal
Verified
Journal Article
Open access
XHXinyan Huang
Xinyan Huang
JBJianhang Bao
Jianhang Bao
JZJiaqi Zhu
Jiaqi Zhu
SWShuangyue Wu
Shuangyue Wu
DBDavid Bovard
David Bovard
YRYanfang Ren
Yanfang Ren

3 August 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
JZJiaqi Zhu
Jiaqi Zhu
XHXinyan Huang
Xinyan Huang
SWShuangyue Wu
Shuangyue Wu
XXXU Xiaoran
XU Xiaoran
SWSiyuan Wu
Siyuan Wu
JBJianhang Bao
Jianhang Bao
Dysbiosis-related oral biofilm diseases, particularly dental caries and periodontal diseases, pose major global health challenges because ecological shifts within oral microbial communities enhance biofilm virulence, resilience, and host inflammatory responses. Cannabidiol (CBD), a non-psychoactive phytocannabinoid with antimicrobial, antibiofilm, immunomodulatory, and antioxidant properties, has attracted increasing interest as an investigational, ecology-oriented adjunct for oral health applications. This narrative review evaluates current antibiofilm, antivirulence, and host response evidence for CBD in dysbiosis-related oral biofilm diseases, with emphasis on dental caries and periodontal diseases and selected supportive evidence from other oral biofilm-associated conditions. Current evidence suggests that CBD can inhibit biofilm formation, attenuate cariogenic and fungal virulence traits, modulate periodontal inflammation and immunity, and support tissue-protective responses. However, most evidence remains preclinical and model-dependent, particularly in caries research, and CBD’s hydrophobicity, limited stability, uncertain dose windows, and incomplete microbiome-level evidence remain major barriers to translation. Future studies should clarify CBD’s ecological effects on oral microbial communities, define clinically relevant dosing and exposure timing, and develop oral-retentive delivery systems.